Yin Ting Cheung1, Tara M Brinkman1,2, Daniel A Mulrooney1,3, Yasmin Mzayek1, Wei Liu4, Pia Banerjee1, Angela Panoskaltsis-Mortari5,6, Deokumar Srivastava4, Ching-Hon Pui3, Leslie L Robison1, Melissa M Hudson1,3, Kevin R Krull1,2. 1. Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee. 2. Department of Psychology, St. Jude Children's Research Hospital, Memphis, Tennessee. 3. Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee. 4. Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee. 5. Division of Pediatric Blood and Bone Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota. 6. Department of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Minnesota, Minneapolis, Minnesota.
Abstract
BACKGROUND: Long-term survivors of childhood acute lymphoblastic leukemia (ALL) are at risk for neurocognitive impairment, which may be associated with fatigue, sleep problems, systemic inflammation, and oxidative stress. We examined these associations among survivors of childhood ALL treated with chemotherapy only. METHODS: Survivors of childhood ALL (male, n = 35 and female, n = 35; mean age, 14.3 years [standard deviation, 4.7 years] and mean years from diagnosis, 7.4 years [standard deviation, 1.9 years]) completed neurocognitive testing, behavioral ratings, and reported sleep quality and fatigue symptoms 5 years after diagnosis. Serum was collected concurrently and assayed for interleukin (IL)-1β and IL-6, tumor necrosis factor α (TNF-α), high-sensitivity C-reactive protein (hsCRP), malondialdehyde, myeloperoxidase, and oxidized low-density lipoprotein. General linear modeling was used to assess associations among biomarkers and functional outcomes, adjusting for age and stratified by sex. RESULTS: Survivors performed worse than population norms on executive function and processing speed and reported more behavioral problems (P < .05 adjusted for multiple comparison). In female survivors, fatigue was associated with poor executive function (r = 0.41; P = .02), processing speed (r = 0.56; P < .001), and attention (r = 0.36-0.55; P < .05). Female survivors with frequent nighttime awakening displayed more inattention (P = .01), hyperactivity (P = .03), and aggression (P = .01). Worse executive function, processing speed, and behavioral symptoms were observed in female survivors with higher levels of IL-6, IL-1β, and hsCRP (P < .05). Male survivors with high levels of TNF-α demonstrated worse organization (P = .03), but no significant associations between neurocognitive outcomes and sleep/fatigue measures were observed. CONCLUSION: Neurocognitive function in female survivors of childhood ALL appears more susceptible to the effects of sleep disturbance and fatigue. Systemic inflammation may play a role in neurocognitive impairment and behavioral symptoms. Cancer 2017;123:3410-9.
BACKGROUND: Long-term survivors of childhood acute lymphoblastic leukemia (ALL) are at risk for neurocognitive impairment, which may be associated with fatigue, sleep problems, systemic inflammation, and oxidative stress. We examined these associations among survivors of childhood ALL treated with chemotherapy only. METHODS: Survivors of childhood ALL (male, n = 35 and female, n = 35; mean age, 14.3 years [standard deviation, 4.7 years] and mean years from diagnosis, 7.4 years [standard deviation, 1.9 years]) completed neurocognitive testing, behavioral ratings, and reported sleep quality and fatigue symptoms 5 years after diagnosis. Serum was collected concurrently and assayed for interleukin (IL)-1β and IL-6, tumor necrosis factor α (TNF-α), high-sensitivity C-reactive protein (hsCRP), malondialdehyde, myeloperoxidase, and oxidized low-density lipoprotein. General linear modeling was used to assess associations among biomarkers and functional outcomes, adjusting for age and stratified by sex. RESULTS: Survivors performed worse than population norms on executive function and processing speed and reported more behavioral problems (P < .05 adjusted for multiple comparison). In female survivors, fatigue was associated with poor executive function (r = 0.41; P = .02), processing speed (r = 0.56; P < .001), and attention (r = 0.36-0.55; P < .05). Female survivors with frequent nighttime awakening displayed more inattention (P = .01), hyperactivity (P = .03), and aggression (P = .01). Worse executive function, processing speed, and behavioral symptoms were observed in female survivors with higher levels of IL-6, IL-1β, and hsCRP (P < .05). Male survivors with high levels of TNF-α demonstrated worse organization (P = .03), but no significant associations between neurocognitive outcomes and sleep/fatigue measures were observed. CONCLUSION: Neurocognitive function in female survivors of childhood ALL appears more susceptible to the effects of sleep disturbance and fatigue. Systemic inflammation may play a role in neurocognitive impairment and behavioral symptoms. Cancer 2017;123:3410-9.
Authors: Janet M Mullington; Norah S Simpson; Hans K Meier-Ewert; Monika Haack Journal: Best Pract Res Clin Endocrinol Metab Date: 2010-10 Impact factor: 4.690
Authors: See Wan Tham; Tonya M Palermo; Monica S Vavilala; Jin Wang; Kenneth M Jaffe; Thomas D Koepsell; Andrea Dorsch; Nancy Temkin; Dennis Durbin; Frederick P Rivara Journal: J Neurotrauma Date: 2012-01-01 Impact factor: 5.269
Authors: Kevin R Krull; Yin Ting Cheung; Wei Liu; Slim Fellah; Wilburn E Reddick; Tara M Brinkman; Cara Kimberg; Robert Ogg; Deokumar Srivastava; Ching-Hon Pui; Leslie L Robison; Melissa M Hudson Journal: J Clin Oncol Date: 2016-06-06 Impact factor: 44.544
Authors: Marilyn J Hockenberry; Mary C Hooke; Maryann Gregurich; Kathy McCarthy; Gennaro Sambuco; Kevin Krull Journal: Oncol Nurs Forum Date: 2010-01 Impact factor: 2.172
Authors: Andrew W Gardner; Donald E Parker; Polly S Montgomery; Danuta Sosnowska; Ana I Casanegra; Zoltan Ungvari; Anna Csiszar; William E Sonntag Journal: J Vasc Surg Date: 2014-04-03 Impact factor: 4.268
Authors: Yin Ting Cheung; Tara M Brinkman; Chenghong Li; Yasmin Mzayek; Deokumar Srivastava; Kirsten K Ness; Sunita K Patel; Rebecca M Howell; Kevin C Oeffinger; Leslie L Robison; Gregory T Armstrong; Kevin R Krull Journal: J Natl Cancer Inst Date: 2018-04-01 Impact factor: 13.506
Authors: Erik Boberg; Nadir Kadri; Jeanette Winterling; Lindsay C Davies; Andreas Björklund; Mussie Msghina; Ellen Iacobaeus; Katarina Le Blanc Journal: Haematologica Date: 2019-10-24 Impact factor: 9.941
Authors: Kevin R Krull; Kristina K Hardy; Lisa S Kahalley; Ilse Schuitema; Shelli R Kesler Journal: J Clin Oncol Date: 2018-06-06 Impact factor: 44.544
Authors: Priscilla Vasquez; Johanna Escalante; Kimberly P Raghubar; Lisa S Kahalley; Olga A Taylor; Ida Ki Moore; Marilyn J Hockenberry; Michael E Scheurer; Austin L Brown Journal: Pediatr Blood Cancer Date: 2021-12-10 Impact factor: 3.167
Authors: Stephanie B Dixon; Kari L Bjornard; Nicole M Alberts; Gregory T Armstrong; Tara M Brinkman; Wassim Chemaitilly; Matthew J Ehrhardt; Israel Fernandez-Pineda; Lisa M Force; Todd M Gibson; Daniel M Green; Carrie R Howell; Sue C Kaste; Anne C Kirchhoff; James L Klosky; Kevin R Krull; John T Lucas; Daniel A Mulrooney; Kirsten K Ness; Carmen L Wilson; Yutaka Yasui; Leslie L Robison; Melissa M Hudson Journal: CA Cancer J Clin Date: 2018-01-29 Impact factor: 508.702
Authors: Ellen van der Plas; Weiyu Qiu; Brian J Nieman; Yutaka Yasui; Qi Liu; Stephanie B Dixon; Nina S Kadan-Lottick; Christopher B Weldon; Brent R Weil; Lisa M Jacola; Todd M Gibson; Wendy Leisenring; Kevin Oeffinger; Melissa M Hudson; Leslie L Robison; Gregory T Armstrong; Kevin R Krull Journal: J Natl Cancer Inst Date: 2021-05-04 Impact factor: 13.506